

Global Urological Cancer Drugs Sales Market Report 2017

<https://marketpublishers.com/r/G5BDF0BA052EN.html>

Date: February 2017

Pages: 128

Price: US\$ 4,000.00 (Single User License)

ID: G5BDF0BA052EN

Abstracts

Notes:

Sales, means the sales volume of Urological Cancer Drugs

Revenue, means the sales value of Urological Cancer Drugs

This report studies sales (consumption) of Urological Cancer Drugs in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

Tolmar Inc

Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Urological Cancer Drugs in these regions, from 2011 to 2021 (forecast), like

United States

China

Europe

Japan

Southeast Asia

India

Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

Xtandi (Enzalutamide)

Opdivo (Nivolumab)

Provenge (Sipuleucel-T)

Split by applications, this report focuses on sales, market share and growth rate of Urological Cancer Drugs in each application, can be divided into

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Contents

Global Urological Cancer Drugs Sales Market Report 2017

1 UROLOGICAL CANCER DRUGS OVERVIEW

- 1.1 Product Overview and Scope of Urological Cancer Drugs
- 1.2 Classification of Urological Cancer Drugs
 - 1.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 1.2.2 Jevtana (Cabazitaxel)
 - 1.2.3 Inlyta (Axitinib)
 - 1.2.4 Votrient (Pazopanib Hydrochloride)
 - 1.2.5 Sutent (Sunitinib Malate)
 - 1.2.6 Zytiga (Abiraterone Acetate)
 - 1.2.7 Xtandi (Enzalutamide)
 - 1.2.8 Opdivo (Nivolumab)
 - 1.2.9 Provenge (Sipuleucel-T)
- 1.3 Application of Urological Cancer Drugs
 - 1.3.1 Prostate Cancer
 - 1.3.2 Bladder Cancer
 - 1.3.3 Kidney Cancer
 - 1.3.4 Testicular Cancer
- 1.4 Urological Cancer Drugs Market by Regions
 - 1.4.1 United States Status and Prospect (2012-2022)
 - 1.4.2 China Status and Prospect (2012-2022)
 - 1.4.3 Europe Status and Prospect (2012-2022)
 - 1.4.4 Japan Status and Prospect (2012-2022)
 - 1.4.5 Southeast Asia Status and Prospect (2012-2022)
 - 1.4.6 India Status and Prospect (2012-2022)
- 1.5 Global Market Size (Value and Volume) of Urological Cancer Drugs (2012-2022)
 - 1.5.1 Global Urological Cancer Drugs Sales and Growth Rate (2012-2022)
 - 1.5.2 Global Urological Cancer Drugs Revenue and Growth Rate (2012-2022)

2 GLOBAL UROLOGICAL CANCER DRUGS COMPETITION BY MANUFACTURERS, TYPE AND APPLICATION

- 2.1 Global Urological Cancer Drugs Market Competition by Manufacturers
 - 2.1.1 Global Urological Cancer Drugs Sales and Market Share of Key Manufacturers (2012-2017)

2.1.2 Global Urological Cancer Drugs Revenue and Share by Manufacturers
(2012-2017)

2.2 Global Urological Cancer Drugs (Volume and Value) by Type

2.2.1 Global Urological Cancer Drugs Sales and Market Share by Type (2012-2017)

2.2.2 Global Urological Cancer Drugs Revenue and Market Share by Type
(2012-2017)

2.3 Global Urological Cancer Drugs (Volume and Value) by Regions

2.3.1 Global Urological Cancer Drugs Sales and Market Share by Regions
(2012-2017)

2.3.2 Global Urological Cancer Drugs Revenue and Market Share by Regions
(2012-2017)

2.4 Global Urological Cancer Drugs (Volume) by Application

3 UNITED STATES UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

3.1 United States Urological Cancer Drugs Sales and Value (2012-2017)

3.1.1 United States Urological Cancer Drugs Sales and Growth Rate (2012-2017)

3.1.2 United States Urological Cancer Drugs Revenue and Growth Rate (2012-2017)

3.1.3 United States Urological Cancer Drugs Sales Price Trend (2012-2017)

3.2 United States Urological Cancer Drugs Sales and Market Share by Manufacturers

3.3 United States Urological Cancer Drugs Sales and Market Share by Type

3.4 United States Urological Cancer Drugs Sales and Market Share by Application

4 CHINA UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

4.1 China Urological Cancer Drugs Sales and Value (2012-2017)

4.1.1 China Urological Cancer Drugs Sales and Growth Rate (2012-2017)

4.1.2 China Urological Cancer Drugs Revenue and Growth Rate (2012-2017)

4.1.3 China Urological Cancer Drugs Sales Price Trend (2012-2017)

4.2 China Urological Cancer Drugs Sales and Market Share by Manufacturers

4.3 China Urological Cancer Drugs Sales and Market Share by Type

4.4 China Urological Cancer Drugs Sales and Market Share by Application

5 EUROPE UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

5.1 Europe Urological Cancer Drugs Sales and Value (2012-2017)

5.1.1 Europe Urological Cancer Drugs Sales and Growth Rate (2012-2017)

- 5.1.2 Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
- 5.1.3 Europe Urological Cancer Drugs Sales Price Trend (2012-2017)
- 5.2 Europe Urological Cancer Drugs Sales and Market Share by Manufacturers
- 5.3 Europe Urological Cancer Drugs Sales and Market Share by Type
- 5.4 Europe Urological Cancer Drugs Sales and Market Share by Application

6 JAPAN UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 6.1 Japan Urological Cancer Drugs Sales and Value (2012-2017)
 - 6.1.1 Japan Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 6.1.2 Japan Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 6.1.3 Japan Urological Cancer Drugs Sales Price Trend (2012-2017)
- 6.2 Japan Urological Cancer Drugs Sales and Market Share by Manufacturers
- 6.3 Japan Urological Cancer Drugs Sales and Market Share by Type
- 6.4 Japan Urological Cancer Drugs Sales and Market Share by Application

7 SOUTHEAST ASIA UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 7.1 Southeast Asia Urological Cancer Drugs Sales and Value (2012-2017)
 - 7.1.1 Southeast Asia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 7.1.2 Southeast Asia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 7.1.3 Southeast Asia Urological Cancer Drugs Sales Price Trend (2012-2017)
- 7.2 Southeast Asia Urological Cancer Drugs Sales and Market Share by Manufacturers
- 7.3 Southeast Asia Urological Cancer Drugs Sales and Market Share by Type
- 7.4 Southeast Asia Urological Cancer Drugs Sales and Market Share by Application

8 INDIA UROLOGICAL CANCER DRUGS (VOLUME, VALUE AND SALES PRICE)

- 8.1 India Urological Cancer Drugs Sales and Value (2012-2017)
 - 8.1.1 India Urological Cancer Drugs Sales and Growth Rate (2012-2017)
 - 8.1.2 India Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
 - 8.1.3 India Urological Cancer Drugs Sales Price Trend (2012-2017)
- 8.2 India Urological Cancer Drugs Sales and Market Share by Manufacturers
- 8.3 India Urological Cancer Drugs Sales and Market Share by Type
- 8.4 India Urological Cancer Drugs Sales and Market Share by Application

9 GLOBAL UROLOGICAL CANCER DRUGS MANUFACTURERS ANALYSIS

9.1 Novartis

9.1.1 Company Basic Information, Manufacturing Base and Competitors

9.1.2 Urological Cancer Drugs Product Type, Application and Specification

9.1.2.1 Xofigo (Radium Ra 223 Dichloride)

9.1.2.2 Jevtana (Cabazitaxel)

9.1.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.1.4 Main Business/Business Overview

9.2 Pfizer

9.2.1 Company Basic Information, Manufacturing Base and Competitors

9.2.2 Urological Cancer Drugs Product Type, Application and Specification

9.2.2.1 Xofigo (Radium Ra 223 Dichloride)

9.2.2.2 Jevtana (Cabazitaxel)

9.2.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.2.4 Main Business/Business Overview

9.3 Johnson & Johnson

9.3.1 Company Basic Information, Manufacturing Base and Competitors

9.3.2 Urological Cancer Drugs Product Type, Application and Specification

9.3.2.1 Xofigo (Radium Ra 223 Dichloride)

9.3.2.2 Jevtana (Cabazitaxel)

9.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.3.4 Main Business/Business Overview

9.4 AstraZeneca

9.4.1 Company Basic Information, Manufacturing Base and Competitors

9.4.2 Urological Cancer Drugs Product Type, Application and Specification

9.4.2.1 Xofigo (Radium Ra 223 Dichloride)

9.4.2.2 Jevtana (Cabazitaxel)

9.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.4.4 Main Business/Business Overview

9.5 Astellas

9.5.1 Company Basic Information, Manufacturing Base and Competitors

9.5.2 Urological Cancer Drugs Product Type, Application and Specification

9.5.2.1 Xofigo (Radium Ra 223 Dichloride)

9.5.2.2 Jevtana (Cabazitaxel)

9.5.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.5.4 Main Business/Business Overview

9.6 Bristol-Myers Squibb

9.6.1 Company Basic Information, Manufacturing Base and Competitors

9.6.2 Urological Cancer Drugs Product Type, Application and Specification

9.6.2.1 Xofigo (Radium Ra 223 Dichloride)

9.6.2.2 Jevtana (Cabazitaxel)

9.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.6.4 Main Business/Business Overview

9.7 Abbott Laboratories

9.7.1 Company Basic Information, Manufacturing Base and Competitors

9.7.2 Urological Cancer Drugs Product Type, Application and Specification

9.7.2.1 Xofigo (Radium Ra 223 Dichloride)

9.7.2.2 Jevtana (Cabazitaxel)

9.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.7.4 Main Business/Business Overview

9.8 Celgene Corporation

9.8.1 Company Basic Information, Manufacturing Base and Competitors

9.8.2 Urological Cancer Drugs Product Type, Application and Specification

9.8.2.1 Xofigo (Radium Ra 223 Dichloride)

9.8.2.2 Jevtana (Cabazitaxel)

9.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.8.4 Main Business/Business Overview

9.9 Dendreon Corporation

9.9.1 Company Basic Information, Manufacturing Base and Competitors

9.9.2 Urological Cancer Drugs Product Type, Application and Specification

9.9.2.1 Xofigo (Radium Ra 223 Dichloride)

9.9.2.2 Jevtana (Cabazitaxel)

9.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

9.9.4 Main Business/Business Overview

9.10 Ferring Pharmaceuticals

9.10.1 Company Basic Information, Manufacturing Base and Competitors

9.10.2 Urological Cancer Drugs Product Type, Application and Specification

9.10.2.1 Xofigo (Radium Ra 223 Dichloride)

9.10.2.2 Jevtana (Cabazitaxel)

9.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and

Gross Margin (2012-2017)

9.10.4 Main Business/Business Overview

9.11 GlaxoSmithKline

9.12 Indevus Pharmaceuticals Inc

9.13 Ipsen

9.14 Roche Healthcare

9.15 Sanofi S.A.

9.16 Tolmar Inc

10 UROLOGICAL CANCER DRUGS MAUFACTURING COST ANALYSIS

10.1 Urological Cancer Drugs Key Raw Materials Analysis

10.1.1 Key Raw Materials

10.1.2 Price Trend of Key Raw Materials

10.1.3 Key Suppliers of Raw Materials

10.1.4 Market Concentration Rate of Raw Materials

10.2 Proportion of Manufacturing Cost Structure

10.2.1 Raw Materials

10.2.2 Labor Cost

10.2.3 Manufacturing Process Analysis of Urological Cancer Drugs

10.3 Manufacturing Process Analysis of Urological Cancer Drugs

11 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

11.1 Urological Cancer Drugs Industrial Chain Analysis

11.2 Upstream Raw Materials Sourcing

11.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015

11.4 Downstream Buyers

12 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

12.1 Marketing Channel

12.1.1 Direct Marketing

12.1.2 Indirect Marketing

12.1.3 Marketing Channel Development Trend

12.2 Market Positioning

12.2.1 Pricing Strategy

12.2.2 Brand Strategy

12.2.3 Target Client

12.3 Distributors/Traders List

13 MARKET EFFECT FACTORS ANALYSIS

13.1 Technology Progress/Risk

13.1.1 Substitutes Threat

13.1.2 Technology Progress in Related Industry

13.2 Consumer Needs/Customer Preference Change

13.3 Economic/Political Environmental Change

14 GLOBAL UROLOGICAL CANCER DRUGS MARKET FORECAST (2017-2022)

14.1 Global Urological Cancer Drugs Sales, Revenue and Price Forecast (2017-2022)

14.1.1 Global Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

14.1.2 Global Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

14.1.3 Global Urological Cancer Drugs Price and Trend Forecast (2017-2022)

14.2 Global Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast by Regions (2017-2022)

14.2.1 United States Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)

14.2.2 China Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)

14.2.3 Europe Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)

14.2.4 Japan Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)

14.2.5 Southeast Asia Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)

14.2.6 India Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)

14.3 Global Urological Cancer Drugs Sales, Revenue and Price Forecast by Type (2017-2022)

14.4 Global Urological Cancer Drugs Sales Forecast by Application (2017-2022)

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

Methodology

Analyst Introduction

Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Urological Cancer Drugs
Table Classification of Urological Cancer Drugs
Figure Global Sales Market Share of Urological Cancer Drugs by Type in 2015
Figure Xofigo (Radium Ra 223 Dichloride) Picture
Figure Jevtana (Cabazitaxel) Picture
Figure Inlyta (Axitinib) Picture
Figure Votrient (Pazopanib Hydrochloride) Picture
Figure Sutent (Sunitinib Malate) Picture
Figure Zytiga (Abiraterone Acetate) Picture
Figure Xtandi (Enzalutamide) Picture
Figure Opdivo (Nivolumab) Picture
Figure Provenge (Sipuleucel-T) Picture
Table Applications of Urological Cancer Drugs
Figure Global Sales Market Share of Urological Cancer Drugs by Application in 2015
Figure Prostate Cancer Examples
Figure Bladder Cancer Examples
Figure Kidney Cancer Examples
Figure Testicular Cancer Examples
Figure United States Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure China Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Japan Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Southeast Asia Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure India Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Global Urological Cancer Drugs Sales and Growth Rate (2012-2022)
Figure Global Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Table Global Urological Cancer Drugs Sales of Key Manufacturers (2012-2017)
Table Global Urological Cancer Drugs Sales Share by Manufacturers (2012-2017)
Figure 2015 Urological Cancer Drugs Sales Share by Manufacturers
Figure 2016 Urological Cancer Drugs Sales Share by Manufacturers
Table Global Urological Cancer Drugs Revenue by Manufacturers (2012-2017)
Table Global Urological Cancer Drugs Revenue Share by Manufacturers (2012-2017)
Table 2015 Global Urological Cancer Drugs Revenue Share by Manufacturers
Table 2016 Global Urological Cancer Drugs Revenue Share by Manufacturers
Table Global Urological Cancer Drugs Sales and Market Share by Type (2012-2017)

Table Global Urological Cancer Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Type (2012-2017)
Figure Global Urological Cancer Drugs Sales Growth Rate by Type (2012-2017)
Table Global Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
Table Global Urological Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Type (2012-2017)
Figure Global Urological Cancer Drugs Revenue Growth Rate by Type (2012-2017)
Table Global Urological Cancer Drugs Sales and Market Share by Regions (2012-2017)
Table Global Urological Cancer Drugs Sales Share by Regions (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Regions (2012-2017)
Figure Global Urological Cancer Drugs Sales Growth Rate by Regions (2012-2017)
Table Global Urological Cancer Drugs Revenue and Market Share by Regions (2012-2017)
Table Global Urological Cancer Drugs Revenue Share by Regions (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Regions (2012-2017)
Figure Global Urological Cancer Drugs Revenue Growth Rate by Regions (2012-2017)
Table Global Urological Cancer Drugs Sales and Market Share by Application (2012-2017)
Table Global Urological Cancer Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Application (2012-2017)
Figure Global Urological Cancer Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure United States Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure United States Urological Cancer Drugs Sales Price Trend (2012-2017)
Table United States Urological Cancer Drugs Sales by Manufacturers (2012-2017)
Table United States Urological Cancer Drugs Market Share by Manufacturers (2012-2017)
Table United States Urological Cancer Drugs Sales by Type (2012-2017)
Table United States Urological Cancer Drugs Market Share by Type (2012-2017)
Table United States Urological Cancer Drugs Sales by Application (2012-2017)
Table United States Urological Cancer Drugs Market Share by Application (2012-2017)
Figure China Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure China Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure China Urological Cancer Drugs Sales Price Trend (2012-2017)
Table China Urological Cancer Drugs Sales by Manufacturers (2012-2017)
Table China Urological Cancer Drugs Market Share by Manufacturers (2012-2017)
Table China Urological Cancer Drugs Sales by Type (2012-2017)
Table China Urological Cancer Drugs Market Share by Type (2012-2017)
Table China Urological Cancer Drugs Sales by Application (2012-2017)

Table China Urological Cancer Drugs Market Share by Application (2012-2017)
Figure Europe Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Europe Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Europe Urological Cancer Drugs Sales by Manufacturers (2012-2017)
Table Europe Urological Cancer Drugs Market Share by Manufacturers (2012-2017)
Table Europe Urological Cancer Drugs Sales by Type (2012-2017)
Table Europe Urological Cancer Drugs Market Share by Type (2012-2017)
Table Europe Urological Cancer Drugs Sales by Application (2012-2017)
Table Europe Urological Cancer Drugs Market Share by Application (2012-2017)
Figure Japan Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Japan Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Japan Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Japan Urological Cancer Drugs Sales by Manufacturers (2012-2017)
Table Japan Urological Cancer Drugs Market Share by Manufacturers (2012-2017)
Table Japan Urological Cancer Drugs Sales by Type (2012-2017)
Table Japan Urological Cancer Drugs Market Share by Type (2012-2017)
Table Japan Urological Cancer Drugs Sales by Application (2012-2017)
Table Japan Urological Cancer Drugs Market Share by Application (2012-2017)
Figure Southeast Asia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Southeast Asia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Southeast Asia Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Southeast Asia Urological Cancer Drugs Sales by Manufacturers (2012-2017)
Table Southeast Asia Urological Cancer Drugs Market Share by Manufacturers (2012-2017)
Table Southeast Asia Urological Cancer Drugs Sales by Type (2012-2017)
Table Southeast Asia Urological Cancer Drugs Market Share by Type (2012-2017)
Table Southeast Asia Urological Cancer Drugs Sales by Application (2012-2017)
Table Southeast Asia Urological Cancer Drugs Market Share by Application (2012-2017)
Figure India Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure India Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure India Urological Cancer Drugs Sales Price Trend (2012-2017)
Table India Urological Cancer Drugs Sales by Manufacturers (2012-2017)
Table India Urological Cancer Drugs Market Share by Manufacturers (2012-2017)
Table India Urological Cancer Drugs Sales by Type (2012-2017)
Table India Urological Cancer Drugs Market Share by Type (2012-2017)
Table India Urological Cancer Drugs Sales by Application (2012-2017)
Table India Urological Cancer Drugs Market Share by Application (2012-2017)

Table Novartis Basic Information List

Table Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin
(2012-2017)

Figure Novartis Urological Cancer Drugs Global Market Share (2012-2017)

Table Pfizer Basic Information List

Table Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin
(2012-2017)

Figure Pfizer Urological Cancer Drugs Global Market Share (2012-2017)

Table Johnson & Johnson Basic Information List

Table Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross
Margin (2012-2017)

Figure Johnson & Johnson Urological Cancer Drugs Global Market Share (2012-2017)

Table AstraZeneca Basic Information List

Table AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin
(2012-2017)

Figure AstraZeneca Urological Cancer Drugs Global Market Share (2012-2017)

Table Astellas Basic Information List

Table Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin
(2012-2017)

Figure Astellas Urological Cancer Drugs Global Market Share (2012-2017)

Table Bristol-Myers Squibb Basic Information List

Table Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross
Margin (2012-2017)

Figure Bristol-Myers Squibb Urological Cancer Drugs Global Market Share (2012-2017)

Table Abbott Laboratories Basic Information List

Table Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross
Margin (2012-2017)

Figure Abbott Laboratories Urological Cancer Drugs Global Market Share (2012-2017)

Table Celgene Corporation Basic Information List

Table Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross
Margin (2012-2017)

Figure Celgene Corporation Urological Cancer Drugs Global Market Share (2012-2017)

Table Dendreon Corporation Basic Information List

Table Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross
Margin (2012-2017)

Figure Dendreon Corporation Urological Cancer Drugs Global Market Share
(2012-2017)

Table Ferring Pharmaceuticals Basic Information List

Table Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and

Gross Margin (2012-2017)

Figure Ferring Pharmaceuticals Urological Cancer Drugs Global Market Share (2012-2017)

Table GlaxoSmithKline Basic Information List

Table Indevus Pharmaceuticals Inc Basic Information List

Table Ipsen Basic Information List

Table Roche Healthcare Basic Information List

Table Sanofi S.A. Basic Information List

Table Tolmar Inc Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Urological Cancer Drugs

Figure Manufacturing Process Analysis of Urological Cancer Drugs

Figure Urological Cancer Drugs Industrial Chain Analysis

Table Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015

Table Major Buyers of Urological Cancer Drugs

Table Distributors/Traders List

Figure Global Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)

Figure Global Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Table Global Urological Cancer Drugs Sales Forecast by Regions (2017-2022)

Table Global Urological Cancer Drugs Sales Forecast by Type (2017-2022)

Table Global Urological Cancer Drugs Sales Forecast by Application (2017-2022)

I would like to order

Product name: Global Urological Cancer Drugs Sales Market Report 2017

Product link: <https://marketpublishers.com/r/G5BDF0BA052EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5BDF0BA052EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970